- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04602689
Fibrin Glue After ESD for High Risk Patients of Bleeding
Effectiveness of Fibrin Glue to Prevent Bleeding in High-risk Patients After Endoscopic Submucosal Dissection in Gastric Neoplasm : A Prospective Randomized Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Investigators want to observe the bleeding rate after endoscopic submucosal dissection for gastric tumors in the high-risk group of bleeding (the size of the iatrogenic ulcer is expected to be 40mm or more, or taking aspirin, antiplatelet drugs, and anticoagulants).
After resection and hemostasis with ESD, Fibrin glue (Greenplast Q™) is applied to the iatrogenic ulcer at the end of the procedure, and the control group will not be applied.
After that, observe whether there is a difference in the bleeding rate within 48 hours and 4 weeks.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eunwoo Lee, M.D.
- Phone Number: 82-10-9404-9109
- Email: rfsquid@naver.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Contact:
- Eunwoo Lee, M.D.
- Phone Number: 82-10-9404-9109
- Email: rfsquid@naver.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ECOG performance status 0-1
- Patients scheduled to undergo ESD due to gastric tumor (dysplasia, early gastric cancer)
- Patients who are expected to have an iatrogenic ulcer size of 40mm or more after endoscopic submucosal dissection, or are taking aspirin, antiplatelet drugs, or anticoagulants
- Patients who show adequate patient compliance and have adequate geographic distance for follow-up observation.
Exclusion Criteria:
- Patients with sensitivity to cow protein or its derived ingredients
- Patients who had previously undergone partial gastrectomy
- Patients with early gastric cancer at the site previously undergoing ESD
- Patients with clinically significant cardiopulmonary disease
- Patients with active hepatitis, liver disease that is not well controlled by treatment, or severe liver disorder
- Patients with severe renal impairment
- Patients with severe bone marrow dysfunction
- Patients with severe blood clotting impairment (including hemophilia)
- Patients with serious neurological or mental illness (e.g. epilepsy or dementia)
- Patients with reported side effects of contrast media
- Pregnant and lactating women
- Patients who have not obtained the informed consent of the patient and guardian
- Patients who are inadequate for clinical trials as judged by the attending physician
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Fibrin glue group
Spread Fibrin glue(Greenplast Q™) at iatrogenic ulcer after gastric ESD
|
Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD
|
NO_INTERVENTION: Control group
No intervention after gastric ESD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bleeding after ESD
Time Frame: 4 weeks
|
Number of gastrointestinal bleeding events within 4 weeks after the procedure
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early bleeding after ESD
Time Frame: 48 hours
|
Number of gastrointestinal bleeding events within 48 hours after the procedure
|
48 hours
|
Delayed bleeding after ESD
Time Frame: from 48 hours to 4 weeks
|
Number of gastrointestinal bleeding events from 48 hours to 4 weeks after the procedure
|
from 48 hours to 4 weeks
|
Collaborators and Investigators
Investigators
- Study Director: Eunwoo Lee, M.D., Fellowship
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2004-093-1117
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early Gastric Cancer
-
Soonchunhyang University HospitalCompletedEarly Gastric Cancer | Gastric DysplasiaKorea, Republic of
-
Seoul National University HospitalUnknownEarly Gastric Cancer | Gastric TumorKorea, Republic of
-
Yonsei UniversityCompletedEarly Gastric Cancer | Gastric AdenomaKorea, Republic of
-
Yonsei UniversityCompletedEarly Gastric Cancer | Gastric AdenomaKorea, Republic of
-
Sohag UniversityNot yet recruiting
-
RenJi HospitalUnknown
-
National Cancer Center, KoreaUnknown
-
Shanghai Zhongshan HospitalUnknown
-
Beijing Friendship HospitalUnknown
-
Yonsei UniversityCompletedEarly Gastric CancerKorea, Republic of
Clinical Trials on Human fibrinogen concentrate
-
Medical University InnsbruckCompletedTrauma | Massive HemorrhageAustria, Czech Republic, Germany
-
University of VirginiaOctapharmaCompletedBleeding | Pediatric HDUnited States
-
Laboratoire français de Fractionnement et de BiotechnologiesCompletedHypofibrinogenemia, Congenital | Afibrinogenemia, CongenitalFrance, Lebanon, Morocco, Turkey
-
BiotestAccovion GmbH; ICON plc; SYNLAB Analytics and Services Germany GmbH; Phoenix Clinical... and other collaboratorsCompletedCongenital Afibrinogenemia | Congenital HypofibrinogenemiaBulgaria, Egypt, Germany, Lebanon, Tunisia
-
Laboratoire français de Fractionnement et de BiotechnologiesCompleted
-
Grifols Therapeutics LLCInstituto Grifols, S.A.CompletedCongenital AfibrinogenemiaIndia, United States, Italy, Lebanon
-
CSL BehringCompleted
-
University Children's Hospital, ZurichCompletedHemorrhage | Blood Coagulation DisordersSwitzerland
-
Centre Hospitalier Universitaire de Saint EtienneInstitut de Cancérologie de la LoireRecruitingBleeding | Platelet Refractoriness | Hematological PatientsFrance
-
Nicklaus Children's Hospital f/k/a Miami Children...CompletedAfibrinogenemia | Hypofibrinogenemia | Bleeding DisordersUnited States